OTCMKTS:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis $2.28 +0.05 (+2.24%) As of 02:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Propanc Biopharma Stock (OTCMKTS:PPCB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Propanc Biopharma alerts:Sign Up Key Stats Today's Range$2.11▼$2.4050-Day Range$1.73▼$10.4052-Week Range$1.25▼$145.46Volume645,952 shsAverage Volume842,266 shsMarket Capitalization$26.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents. The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth. Propanc has conducted toxicology studies and in vitro assessments to establish safety profiles and enzyme stability, and it continues to advance its candidates through formulation optimization and manufacturing scale-up. In parallel, Propanc explores potential combination regimens with established oncology drugs to support future clinical trial designs. Headquartered in Perth, Western Australia, with additional research collaborations in North America, Propanc Biopharma serves a global oncology community through its development partnerships and licensing discussions. The company is governed by a board and executive team with experience in biotechnology, protein engineering and clinical development, and it aims to position its enzyme-based platform as a complementary approach to existing cancer therapies.AI Generated. May Contain Errors. Read More Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPCB Stock News HeadlinesPropanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark OfficeSeptember 17 at 8:45 AM | globenewswire.comPropanc Biopharma Announces Plan to Acquire $100 Million of EthereumSeptember 2, 2025 | globenewswire.comWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 17 at 2:00 AM | Banyan Hill Publishing (Ad)D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. in Connection with its $4,000,000 UplistingAugust 28, 2025 | finanznachrichten.deD. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 UplistingAugust 28, 2025 | finance.yahoo.comPropanc Biopharma raises $4 million in Nasdaq debut, plans cancer trialsAugust 26, 2025 | investing.comPropanc Biopharma Provides Shareholder UpdateAugust 25, 2025 | globenewswire.comPropanc Biopharma, Inc.: Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQAugust 20, 2025 | finanznachrichten.deSee More Headlines PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed this year? Propanc Biopharma's stock was trading at $0.0002 on January 1st, 2025. Since then, PPCB shares have increased by 1,119,900.0% and is now trading at $2.24. How were Propanc Biopharma's earnings last quarter? Propanc Biopharma Inc (OTCMKTS:PPCB) posted its earnings results on Thursday, May, 15th. The company reported ($12.50) earnings per share for the quarter. When did Propanc Biopharma's stock split? Propanc Biopharma's stock reverse split on the morning of Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. When does Propanc Biopharma's quiet period expire? Propanc Biopharma's quiet period expires on Wednesday, September 24th. Propanc Biopharma had issued 1,000,000 shares in its IPO on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00. During Propanc Biopharma's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH). Company Calendar Last Earnings5/15/2025Today9/17/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PPCB CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees1Year Founded2007Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.82 million Net MarginsN/A Pretax MarginN/A Return on Equity-3,652.66% Return on Assets-971.09% Debt Debt-to-Equity Ratio0.01 Current Ratio2.24 Quick Ratio2.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($493.34) per share Price / Book0.00Miscellaneous Outstanding Shares11,612,000Free Float19,000Market Cap$27.29 million OptionableNot Optionable Beta2.66 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:PPCB) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
